These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 14672397)
1. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397 [TBL] [Abstract][Full Text] [Related]
2. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800 [TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
4. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573 [TBL] [Abstract][Full Text] [Related]
5. Concomitant inactivation of p53 and Chk2 in breast cancer. Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075 [TBL] [Abstract][Full Text] [Related]
6. Low expression of bcl-2 in Brca1-associated breast cancers. Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356 [TBL] [Abstract][Full Text] [Related]
7. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935 [TBL] [Abstract][Full Text] [Related]
8. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147 [TBL] [Abstract][Full Text] [Related]
10. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data. Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268 [TBL] [Abstract][Full Text] [Related]
12. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863 [TBL] [Abstract][Full Text] [Related]
14. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411 [TBL] [Abstract][Full Text] [Related]
16. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814 [TBL] [Abstract][Full Text] [Related]
17. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943 [TBL] [Abstract][Full Text] [Related]
18. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697 [TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994 [TBL] [Abstract][Full Text] [Related]
20. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]